A Prospective Multicenter Trial of Octreotide in 24 Patients with Visual Defects Caused by Nonfunctioning and Gonadotropin-Secreting Pituitary Adenomas

Warnet, A; Harris, Alan G.; Renard, Éric; Martin, Dominique; James-Deidier, A; Chaumet-Riffaud, Philippe

doi:10.1097/00006123-199710000-00005

Cited by 61 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among 48 patients with non-functioning adenomas and gonadotrophinomas (25,26), a significant (.20%) tumour shrinkage was documented in only 7 cases (15%). The SSTR scintigraphy using In111-pentreotide was of poor predictive value in one study (25).…”

Section: Discussionmentioning

confidence: 97%

A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies

Saveanu¹,

Morange-Ramos²,

Gunz³

et al. 2001

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Evaluation of the efficiency of somatostatin analogues in the treatment of a mixed luteinizing hormone (LH)-, a-subunit-, prolactin (PRL)-secreting pituitary adenoma. Design: A 30-year-old woman, with amenorrhaea-galactorrhaea, presented with a pituitary macroadenoma. The endocrine evaluation showed high plasma levels of PRL, LH, and a-subunit inhibited by 65%, 65% and 33% respectively under octreotide test (200 mg, s.c.). Long-term treatment with slow release (SR) lanreotide (30 mg/10 days, i.m.) restored menstrual cycles and normalized PRL values. Due to persisting supranormal levels of LH and a-subunit, and to the absence of tumoral shrinkage, the adenoma was resected by the transsphenoidal route. Methods: In vitro characterization of the somatostatin receptor subtypes (SSTR) expression and functionality. Real-time polymerase chain reaction was performed to quantify the expression of SSTR mRNAs and functionality of the SSTRs was assessed in cell culture studies with various concentrations of native somatostatin (SRIF-14) and of analogues preferential for SSTR2 or SSTR5.Results: This adenoma presented with high levels of SSTR2, SSTR3 and SSTR5 mRNAs, as compared with a series of gonadotroph adenomas. In cell culture studies, PRL, LH and a-subunit were inhibited by 60%, 47% and 33% respectively by SRIF-14 at a concentration of 10 nmol/l. The SSTR2 (BIM-23197, lanreotide) and SSTR5 (BIM-23268) preferential analogues both produced a partial 21±38% inhibition of PRL, LH, and a-subunit release. Discussion: In this plurihormonal-secreting adenoma, the high efficacy of somatostatin analogues to inhibit PRL, LH and a-subunit secretion in vivo may be explained by the unusually high level of expression and by the functionality of both SSTR2 and SSTR5 receptor subtypes.

show abstract

Section: Discussionmentioning

confidence: 97%

A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies

Saveanu¹,

Morange-Ramos²,

Gunz³

et al. 2001

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In vitro, they produce a 28-34% inhibition of FSH, LH, or a-subunit release in 28% of cases (Klibanski et al 1991, de Bruin et al 1992, Hofland et al 1997) and the efficacy of octreotide in inducing tumor shrinkage in vivo is even less impressive and poorly conclusive. Among 48 patients with NFPAs, a O20% reduction in the maximal tumor diameter was reported in seven cases (Plockinger et al 1994, Warnet et al 1997. Medical treatment, using the dopamine agonist bromocriptine, also shows efficacy in reducing tumor mass in few patients with NFPAs (van Schaardenburg et al 1989).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study

Florio¹,

Barbieri²,

Spaziante³

et al. 2008

Endocrine Related Cancer

View full text Add to dashboard Cite

Dopamine D2 and somatostatin receptors (sstrs) were reported to affect non-functioning pituitary adenoma (NFPA) proliferation in vitro. However, the reported results differ according to the experimental conditions used. We established an experimental protocol allowing reproducible evaluation of NFPA cell proliferation in vitro, to test and compare the antiproliferative effects of dopamine and somatostatin analogs (alone or in combination) with the activity of the dopamine-somatostatin chimeric molecule BIM-23A760. The protocol was utilized by four independent laboratories, studying 38 fibroblast-deprived NFPA cell cultures. Cells were characterized for GH, POMC, sstr1-sstr5, total dopamine D2 receptor (D2R) (in all cases), and D2 receptor long and short isoforms (in 15 out of 38 cases) mRNA expression and for a-subunit, LH, and FSH release. D2R, sstr3, and sstr2 mRNAs were consistently observed, with the dominant expression of D2R (2.9G2.6 copy/copy b-glucuronidase; meanGS.E.M.), when compared with sstr3 and sstr2 (0.6G1.0 and 0.3G0.6 respectively). BIM-23A760, a molecule with high affinity for D2R and sstr2, significantly inhibited [ 3 H]thymidine incorporation in 23 out of 38 (60%) NFPA cultures (EC 50 Z1.2 pM and E max ZK33.6G3.7%). BIM-23A760 effects were similar to those induced by the selective D2R agonist cabergoline that showed a statistically significant inhibition in 18 out of 27 tumors (compared with a significant inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases. In conclusion, superimposable data generated in four independent laboratories using a standardized protocol demonstrate that, in vitro, chimeric dopamine/sstr agonists are effective in inhibiting cell proliferation in two-thirds of NFPAs.

show abstract

“…The efficacy of SSA in the treatment of NFPA was evaluated in a few clinical studies [8,9]. Stabilisation of adenoma size was observed in the overwhelming majority of patients; however, single cases of tumour shrinkage were also noted [10,11]. It is difficult to draw definite conclusions because of limited clinical data and short duration of therapy.…”

Section: Introductionmentioning

confidence: 99%

Ocena efektów leczenia analogami somatostatyny nieczynnych hormonalnie gruczolaków przysadki w porównaniu z akromegalią

Zawada

Kunert‐Radek

Pawlikowski

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

A Prospective Multicenter Trial of Octreotide in 24 Patients with Visual Defects Caused by Nonfunctioning and Gonadotropin-Secreting Pituitary Adenomas

Cited by 61 publications

References 21 publications

A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies

A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study

Ocena efektów leczenia analogami somatostatyny nieczynnych hormonalnie gruczolaków przysadki w porównaniu z akromegalią

Contact Info

Product

Resources

About